Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes

Arthritis and Rheumatism

Volumn 54, Issue 1, 2006, Pages 253-263

  Steenvoorden, Marjan M C ^a   Huizinga, Tom W J ^a   Verzijl, Nicole ^b   Bank, Ruud A ^c   Ronday, H Karel ^d   Luning, Hilco A F ^d   Lafeber, Floris P J G ^e   Toes, René E M ^a   DeGroot, Jeroen ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; COLLAGEN TYPE 2; GLYCOSYLATED ALBUMIN; INTERSTITIAL COLLAGENASE; MATRIX PROTEIN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PENTOSIDINE;

ADULT; AGED; AGING; ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYNOVIOCYTE;

CADAVER; CHONDROCYTES; FIBROBLASTS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OSTEOARTHRITIS; RECEPTORS, IMMUNOLOGIC; SYNOVIAL MEMBRANE;

EID: 31044444377     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21523     Document Type: Article

References (53)

1. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. I. The disease and its risk factors. Ann Intern Med 2000;133:635-46.
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503-8.
3. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention [review]. Arthritis Rheum 1998;41:1343-55.
4. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. Ageing and osteoarthritis: a different perspective. Curr Opin Rheumatol 2003;15:616-22.
5. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000;275:39027-31.
6. Bank RA, Bayliss MT, Lafeber FP, Maroudas A, TeKoppele JM. Ageing and zonal variation in post-translational modification of collagen in normal human articular cartilage: the age-related increase in non-enzymatic glycation affects biomechanical properties of cartilage. Biochem J 1998;330:345-51.
7. Verzijl N, DeGroot J, Oldehinkel E, Bank RA, Thorpe SR, Baynes JW, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000;350:381-7.
8. Verzijl N, DeGroot J, Zaken CB, Braun-Benjamin O, Maroudas A, Bank RA, et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002;46:114-23.
9. DeGroot J, Bank RA, Tchetverikov I, Verzijl N, TeKoppele JM. Molecular markers for osteoarthritis: the road ahead. Curr Opin Rheumatol 2002;14:585-9.
10. DeGroot J, Verzijl N, Bank RA, Lafeber FP, Bijlsma JW, TeKoppele JM. Age-related decrease in proteoglycan synthesis of human articular chondrocytes: the role of nonenzymatic glycation. Arthritis Rheum 1999;42:1003-9.
11. DeGroot J, Verzijl N, Wenting-van Wijk MJ, Jacobs KM, van El B, van Roermund PM, et al. Accumulation of advanced glycation end products as a molecular mechanism for aging as a risk factor in osteoarthritis. Arthritis Rheum 2004;50:1207-15.
12. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002;3:123-35.
13. Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998;47:1155-7.
14. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002;105:816-22.
15. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
16. Hou FF, Jiang JP, Guo JQ, Wang GB, Zhang X, Stern DM, et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002;13:1296-306.
17. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001;27:535-42.
18. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000;405:354-60.
19. Pages C, Nolo R, Huttunen HJ, Eskelinen E, Rauvala H. Regulation of cell migration by amphoterin. J Cell Sci 2000;113:611-20.
20. Fuchs S, Skwara A, Bloch M, Dankbar B. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthritis Cartilage 2004;12:409-18.
21. ε- carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:488-92.
22. Drinda S, Franke S, Ruster M, Petrow P, Pullig O, Stein G, et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 2005;25:411-3.
23. Chen JR, Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T. Comparison of the concentrations of pentosidine in the synovial fluid, serum and urine of patients with rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 1999;38:1275-8.
24. Owen WF Jr, Hou FF, Stuart RO, Kay J, Boyce J, Chertow GM, et al. β2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Kidney Int 1998;53:1365-73.
25. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
26. Lafeber FP, van der Kraan PM, van Roy JL, Huber-Bruning O, Bijlsma JW. Articular cartilage expiant culture; an appropriate in vitro system to compare osteoarthritic and normal human cartilage. Connect Tissue Res 1993;29:287-99.
27. Bank RA, Beekman B, Verzijl N, de Roos JA, Sakkee AN, TeKoppele JM. Sensitive fluorimetric quantitation of pyridinium and pentosidine crosslinks in biological samples in a single high-performance liquid chromatographic run. J Chromatogr B Biomed Sci Appl 1997;703:37-44.
28. Bank RA, Jansen EJ, Beekman B, TeKoppele JM. Amino acid analysis by reverse-phase high-performance liquid chromatography: improved derivatization and detection conditions with 9-fluorenylmethyl chloroformate. Anal Biochem 1996;240:167-76.
29. Beekman B, Verzijl N, de Roos JA, TeKoppele JM. Matrix degradation by chondrocytes cultured in alginate: IL-1β induces proteoglycan degradation and proMMP synthesis but does not result in collagen degradation. Osteoarthritis Cartilage 1998;6:330-40.
30. Tolboom TC, Pieterman E, van der Laan WH, Toes RE, Huidekoper AL, Nelissen RG, et al. Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002;61:975-80.
31. Van der Laan WH, Quax PH, Seemayer CA, Huisman LG, Pieterman EJ, Grimbergen JM, et al. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003;10:234-42.
32. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005;52:2376-85.
33. DeGroot J, Verzijl N, Jacobs KM, Budde M, Bank RA, Bijlsma JW, et al. Accumulation of advanced glycation endproducts reduces chondrocyte-mediated extracellular matrix turnover in human articular cartilage. Osteoarthritis Cartilage 2001;9:720-6.
34. DeGroot J, Verzijl N, Budde M, Bijlsma JW, Lafeber FP, TeKoppele JM. Accumulation of advanced glycation end products decreases collagen turnover by bovine chondrocytes. Exp Cell Res 2001;266:303-10.
35. Saudek DM, Kay J. Advanced glycation endproducts and osteoarthritis. Curr Rheumatol Rep 2003;5:33-40.
36. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470-8.
37. Waine H, Nevinny D, Rosenthal J, Joffe IB. Association of osteoarthritis and diabetes mellitus. Tufts Folia Med 1961;7:13-9.
38. Silberberg M, Frank EL, Jarret SR, Silberberg R. Aging and osteoarthritis of the human sternoclavicular joint. Am J Pathol 1959;35:851-65.
39. Campbell WL, Feldman F. Bone and soft tissue abnormalities of the upper extremity in diabetes mellitus. Am J Roentgenol Radium Ther Nucl Med 1975;124:7-16.
40. Bagge E, Bjelle A, Eden S, Svanborg A. Factors associated with radiographic osteoarthritis: results from the population study 70-year-old people in Göteborg. J Rheumatol 1991;18:1218-22.
41. Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I): evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988;128:179-89.
42. Fowler MJ Jr, Neff MS, Borghaei RC, Pease EA, Mochan E, Thornton RD. Induction of bone morphogenetic protein-2 by interleukin-1 in human fibroblasts. Biochem Biophys Res Commun 1998;248:450-3.
43. Lories RJ, Derese I, Ceuppens JL, Luyten FP. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 2003;48:2807-18.
44. Zoricic S, Maric I, Bobinac D, Vukicevic S. Expression of bone morphogenetic proteins and cartilage-derived morphogenetic proteins during osteophyte formation in humans. J Anat 2003;202:269-77.
45. Wang EA, Rosen V, d'Alessandro JS, Bauduy M, Cordes P, Harada T, et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990;87:2220-4.
46. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 2003;48:3442-51.
47. Hsieh HL, Schafer BW, Sasaki N, Heizmann CW. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun 2003;307:375-81.
48. Leder A, Kuo A, Cardiff RD, Sinn E, Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci U S A 1990;87:9178-82.
49. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48:971-81.
50. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853-63.
51. McCarthy AD, Etcheverry SB, Bruzzone L, Lettieri G, Barrio DA, Cortizo AM. Non-enzymatic glycosylation of a type I collagen matrix: effects on osteoblastic development and oxidative stress. BMC Cell Biol 2001;2:16-25.
52. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, et al. Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 2001;38 Suppl 1:8161-4.
53. ε-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology (Oxford) 2003;42:1242-6.